Introduction
The currently established treatment of acute promyelocytic leukemia (APL) relies on the combination of all-trans retinoic acid (ATRA) and chemotherapy and results in cure of more than 70% of newly diagnosed patients. [1] [2] [3] [4] [5] [6] [7] Nonetheless, more than 20% of patients presenting with APL still die of their disease. This percentage includes both early death during induction in approximately 10% of patients, mainly owing to hemorrhage and infection, and relapse after appropriate therapy. For these relapsed patients, optimal salvage strategies are not well established and their prognosis is usually considered poor. 8, 9 Arsenic trioxide (ATO) provides a high response rate in this setting and is generally considered as the first option of salvage therapy, although its precise role in the management of relapsed APL, owing to its recent introduction, remains to be definitively defined. [10] [11] [12] [13] [14] [15] [16] [17] Monitoring of minimal residual disease (MRD) during treatment of APL, based on the assessment of the PML/RARa transcript by means of reverse transcription-polymerase chain reaction (RT-PCR), is useful to anticipate overt hematological relapse, as shown by the high predictive value of impending relapse that the persistence or reappearance of this molecular marker after consolidation therapy has. 3, 18, 19 Therefore, analysis of relapse in patients undergoing treatment for APL should include these molecular failures. Preliminary reports indicate that institution of salvage chemotherapy for molecular disease might result in a significantly improved outcome as compared to that of patients treated for an overt hematological relapse, but this observation has not been subsequently confirmed in larger series. 20, 21 With this background, we analyzed the outcome in a series of APL patients treated according to PETHEMA protocols LPA96 and LPA99 4, 7 who experienced a therapeutic failure, defined on the basis of molecular or hematological grounds, and treated according to a highly homogenous salvage therapy based on ATRA and high-dose ara-C-based chemotherapy (HDAC).
Patients and methods

Patients
The study included 52 patients, diagnosed with de novo PML/ RARa-positive APL and treated according to PETHEMA protocols LPA96 and LPA99, who experienced either molecular failure (MOLrel) or hematological overt relapse (HEMrel) during the period between November 1996 and December 2004. 4, 7 Briefly, APL PETHEMA protocols consisted of an induction phase with the AIDA regimen (ATRA 45 mg/m 2 until complete remission (CR) and idarubicin 12 mg/m 2 on days 2-4-6-8), three cycles of anthracycline-based consolidation (idarubicin 5-7 mg/ m 2 Â 4, mitoxantrone 10 mg/m 2 Â 5 and idarubicin 12 mg/ m 2 Â 1-2, respectively), followed by a maintenance therapy with daily oral 6-mercaptopurine, weekly intramuscular methotrexate and intermittent ATRA (45 mg/m 2 Â 15 days every 3 months) for 2 years since diagnosis. LPA99 protocol included a 15-day period of ATRA during consolidation cycles and increased doses of anthracyclines on cycles 1 and 3 for intermediate and high-risk patients. 7, 22 Assessment of minimal residual disease MRD was prospectively monitored by RT-PCR of PML/RARa every 2-3 months during the first year, and every 3 months during the second year. The method used for detection of PML/ RARa leukemic transcript consisted of a low-sensitivity RT-PCR, reported elsewhere. 4, 23 Molecular failures were defined as the persistence of the molecular marker at the end of consolidation therapy (molecular persistence) or its reappearance during subsequent follow-up (molecular relapse). Any PCR positivity was confirmed in an extra bone marrow (BM) sample obtained 2-4 weeks later and sent to one of two reference laboratories (Hospital La Fe of Valencia and Hospital Clínico Universitario of Salamanca).
Salvage therapy
Salvage therapy consisted of a combination of oral ATRA (45 mg/m 2 in two daily doses until CR) and HDAC in most patients (n ¼ 43), according to two different regimens (LPA-97R and LPA-99R). The remaining patients received single-agent ATRA (liposomal ATRA, n ¼ 3; oral ATRA, n ¼ 1), liposomal ATRA combined with idarubicin (n ¼ 1), chemotherapy without ATRA (EMA, n ¼ 1; ICE, n ¼ 1; I þ C, n ¼ 1), and, in a patient with isolated relapse at cerebrospinal fluid, triple intrathecal chemotherapy (methotrexate, cytarabine and prednisone). LPA-97R regimen (n ¼ 11) was based on the combination of ATRA (45 mg/m 2 until CR) and the EMA regimen 8 (ara-C 500 mg/m 2 in continuous infusion, days 2-4 and 9-11; mitoxantrone 12 mg/ m 2 Â days 1-3; VP-16 200 mg/m 2 Â days1-3). On its turn, LPA-99R (n ¼ 32) consisted of an induction cycle containing ATRA (45 mg/m 2 until CR), high-dose ara-C (1 g/m 2 in 2-h infusion Â days 1-6) and mitoxantrone (6 mg/m 2 Â days 1-4), followed by a consolidation course with the same regimen except for a shorter extension of cytarabine (four doses) and a 15-day period of ATRA. Following salvage therapy, autologous stem-cell transplantation (autoSCT) was planned for patients achieving a negative molecular status. In patients with an available HLAidentical donor, allogeneic alloSCT was considered, especially if MRD was detectable. The preparative regimen consisted of a myeloablative scheme in all cases except in a 53-year old patient who underwent an alloSCT with reduced-intensity conditioning (fludarabine 150 mg/m 2 þ melphalan 160 mg/m 2 ). Definitions of response after salvage therapy (CR, failure) followed standard criteria. 24 
Statistical analysis
Characteristics between groups were compared using the w 2 test and, when indicated, Fisher's exact tests. Leukemia-free survival (LFS) was calculated from the date of second response until death or subsequent relapse using the Kaplan-Meier method, and comparison between subgroups was performed with the log-rank test. 25 The risk of relapse (RR) was estimated by the cumulative incidence method, considering death in remission as competing event. 26 Multivariate analysis for survival and disease-free survival (DFS) was performed using the Cox proportional hazards model including variables with a significant value in the univariate analysis (Po0.1). 27 
Results
Characteristics of patients
Main characteristics at diagnosis and relapse of the 52 patients included in the study owing to MOLrel (n ¼ 16) or HEMrel (n ¼ 36) are summarized in Table 1 . Median age of patients at relapse was 37 . The interval between diagnosis and relapse was 15 months, with 73% of events occurring during the first 2 years. Among molecular failures, three cases corresponded to molecular persistence after consolidation therapy whereas the remaining 13 patients were molecular relapses. In addition, 36 patients presented with hematological relapse at the time of salvage treatment, with extramedullary involvement in nine patients (CNS, eight; external auditory canal, one). Regarding these patients with extramedullary disease, the extramedullary site was the only affected area in 3, whereas the remaining six patients harbored simultaneous BM involvement, either at molecular level (n ¼ 2) or exhibiting overt morphologic infiltration (n ¼ 4). Hematological relapse was preceded by an RT-PCR positive test in 11 patients, including four cases of molecular persistence after consolidation, with a median interval between PCR-positive test and clinical relapse of 37 days (9-152). Comparison of patients presenting with MOLrel and those with HEMrel did not show any significant difference concerning main hemato-biological features at diagnosis, front-line treatment and interval diagnosis-relapse (Table 1 ).
Response to salvage therapy Molecular failures. Salvage therapy for patients presenting with a molecular failure consisted of a regimen with HDAC in 15 patients (LPA-97R, n ¼ 5; LPA-99R, n ¼ 10), associated with ATRA in all but one case, and oral ATRA as single-agent therapy in the remaining patient (Table 2) . After first cycle, 12 patients achieved molecular response (molCR, 75%), two died during hypoplasia owing to fungal infection (Mucor spp. and Scedosporium prolificans, respectively), and the remaining two did not respond, including the patient who received single-agent ATRA. Eight patients received a second course of chemotherapy with ATRA (LPA-99R), as consolidation therapy (n ¼ 7) or second induction cycle in one patient failing to first cycle. Overall, all assessable patients who received HDAC combined with ATRA, excluding those patients who experienced a non-leukemic death, achieved second molCR after one (n ¼ 12) or two cycles (n ¼ 1), with no refractory cases being observed in this setting.
A SCT was performed in seven patients in molCR (autoSCT, 6; syngeneic SCT, 1), while the patient with persistent MRD after single-agent ATRA underwent alloSCT from an HLA-identical sibling and attained a long-standing molCR (24 months). Six patients who had achieved second molCR did not undergo SCT due to failure of peripheral blood stem-cell mobilization (n ¼ 2), early relapse (n ¼ 1, at 2 months after achieving second molCR), previous toxicity (n ¼ 2), and patient's refusal (n ¼ 1). Two of these patients received standard maintenance therapy as alternative consolidation. After a median follow-up of 56 months (14-87), four patients experienced hematological relapse, at 2, 6, 7 and 25 months, respectively, after second molCR, whereas none of the patients undergoing SCT or receiving maintenance therapy relapsed. Up to now, three patients died after second molCR, two of them due to progressive disease, and the remaining patient due to toxic myocarditis occurring immediately after autoSCT. Overall, 2-and 5-year survival since time of molecular failure was 75711 and 64714%, respectively, whereas 2-and 5-year LFS and relapse-risk was 71712 and 63714, and 21711 and 30713%, respectively ( Figure 1 ).
Hematological relapses. Therapy administered to the 36 patients with HEMrel is summarized in Table 3 . Most patients (n ¼ 29, 81%) received ATRA combined with HDAC (LPA-97R, n ¼ 7; LPA-99R, n ¼ 22), three patients were treated with liposomal ATRA, and the remaining patients received other schemes (chemotherapy without ATRA, n ¼ 2; idarubicin þ liposomal ATRA, n ¼ 1; triple intrathecal chemotherapy, n ¼ 1). Following this first cycle, 27 patients (75%) achieved second CR (CR2), four patients (11%) showed refractory and the remaining five died before assessment of response (14%). Two of these patients unresponsive to second-line therapy attained CR2 with ATO and mitoxantrone/HDAC, respectively. A consolidation course was administered to 18 patients in CR2. Overall, 21 patients (58%) achieved second molCR, eight patients (22%) achieved PCR-positive CR2 and seven patients (20%) failed to salvage therapy.
Twenty-one patients underwent SCT in CR2, consisting of autoSCT in 12 patients (11 in molecular response, one with persistent MRD) and alloSCT in nine cases, five of whom with detectable MRD. Concerning allogeneic transplants, eight patients received peripheral blood (n ¼ 7) or bone marrow (n ¼ 1) stem cells from an HLA-identical sibling, whereas the remaining patient received an unrelated cord blood unit. After a Table 1 Main characteristics at diagnosis, relapse and front-line therapy received among patients included in the study The extramedullary site of involvement corresponded to CNS in eight patients (meningeal involvement in all with a concomitant tumor in spinal cord in one case), and the external auditive conduct in the remaining one. c Unknown in four patients.
Outcome of relapsed acute promyelocytic leukemia J Esteve et al median follow-up of 26 months (13-85), 18 patients experienced a second relapse at a median interval of 8 months (3-16) following CR2, including all patients with a PCR-positive CR2 and 10 of the 21 patients attaining a second molCR (Figure 2 ). In addition, two patients died following autoSCT and alloSCT, respectively, owing to a transplant-related cause (graft failure and infection, respectively). Overall survival, LFS and relapse risk was 2978, 2979 and 6479% at 2-year after hematological relapse, and 2478, 2979, and 6479%, respectively, at 5-year after this time point (Figure 1 ).
Prognostic factors
The results of univariate analysis of prognostic variables on the outcome after relapse are summarized in Table 4 . Age, with a threshold at 40, gender, and type of relapse (molecular vs hematological) arose as variables with a prognostic impact on survival after relapse. Among patients who achieved second CR, Table 2 Salvage therapy administered and outcome of patients presenting with a molecular failure Abbreviations: alloSCT, allogeneic SCT; autoSCT, autologous stem-cell transplantation (SCT); CCR, continued complete response; CT, chemotherapy; EFS, event-free survival; HDAC, high-dose ara-C; molCR, molecular complete response; rel, relapse; RR, relapse risk; synSCT, syngeneic SCT; TRD, therapy-related death; tx, therapy. Figure 1 Survival after relapse was significantly better in patients presenting with a molecular failure as compared to that of patients presenting with overt hematological relapse. Outcome of relapsed acute promyelocytic leukemia J Esteve et al institution of salvage therapy for molecular failure was associated with a lower relapse risk and a trend to a better LFS, whereas achievement of molCR after second-line therapy resulted in both better LFS and lower RR (Figure 2 ). Multivariate analysis confirmed the favorable impact on survival after relapse of younger age (P ¼ 0.003; RR: 3.3; 95% CI: 1.5-7.4), male gender (P ¼ 0.005; RR: 3.1; 95% CI: 1.4-6.9), and institution of salvage therapy at molecular relapse (P ¼ 0.04; RR: 2.8; 95% CI: 1.04-7.7). Similarly, multivariate analysis performed among patients achieving CR2 confirmed the favorable impact of achievement of second molecular CR (P ¼ 0.04; RR: 2.3; 95% CI: 1.03-5.3) in terms of LFS.
Discussion
Relapse currently constitutes an infrequent event in APL, involving only one-fifth of patients, owing to the high efficacy of front-line treatment. [1] [2] [3] [4] [5] [6] [7] Nonetheless, the adequate management of relapsed patients is still unclear, and scarce studies have analyzed the outcome of these patients in a prospective fashion. 8, 9 In this regard, the present analysis provides a realistic perspective of the prognosis in a subset of patients who received homogenous initial therapy and, in most cases, similar salvage strategy. Thus, prognosis following hematological relapse was dismal with less than 25% long survivors. On the contrary, institution of therapy at the first evidence of molecular disease resulted in a more favorable outcome, reinforcing the rationale for PCR-triggered therapy in APL.
The salvage strategy employed in this study was designed a decade ago, before general availability of newer agents such as arsenic trioxide, and consisted of the combination of HDAC and ATRA, aimed to attain a molecular response. Subsequently, intensification of response by means of an SCT was planned.
The rationale for the use of high-dose ara-C in this setting was based on the efficacy of this agent in relapsed AML, especially in a cohort of patients not previously exposed to this agent. 28, 29 The efficacy of ATRA in patients who have received repeatedly this agent during induction, maintenance, and, as planned in LPA99 trial, also during consolidation, is, however, unclear. Thus, only 50% of patients who had received ATRA during initial therapy responded to this agent given for relapse in a previous study. 30 Several mechanisms of resistance, including the acquisition of mutations in the receptor-binding unit of RAR protein, have been invoked to explain the decreased activity of ATRA in advanced phases of the disease. 31, 32 On the other hand, the choice of transplant modality was mainly based on the PCR status, with alloSCT being the preferred option in patients failing to achieve a molecular response. The relevance of PCR status before transplant has been emphasized in previous studies showing a high risk of recurrence of disease after autologous transplant when a negative molecular status was not attained. 33, 34 The assumption of persistence or reappearance of MRD after consolidation as a treatment failure relies on the high relapse risk observed after a PCR-positive test, provided that a lowsensitivity protocol (i.e., with a sensitivity level between 10 À3 -10
À4
) for detection of the molecular marker is used. 18, 19, 23 As a consequence, immediate initiation of salvage therapy for molecular failures was planned in both protocols once the PCR positive result was confirmed. This strategy proved effective for patients presenting with a molecular failure, with a long-term DFS surpassing 60%, and resulted in a better survival when compared to hematological relapses, supporting the institution of second-line treatment at first evidence of molecular disease, before occurrence of overt relapse. Nonetheless, as the number of molecular relapses was relatively low, a further confirmation of this observation in an additional series would be useful to Table 4 Summary of the analysis on prognostic factors in patients with APL relapsing after ATRA plus anthracycline-based front-line therapy Despite the strategy of MRD surveillance implemented, only one-third of hematological relapses were preceded by a prior PCR-positive test. Several reasons might explain the high proportion of relapses not predicted by a molecular test, such as the lack of compliance of bone marrow sampling, a circumstance that cannot be completely avoided in a multicenter setting, the occurrence of late relapses in a minority of patients, or, interestingly, the short period elapsed between molecular failure and overt morphologic relapse, of only 30 days, observed in this study. In this regard, an intensified schedule of MRD assessment, with more frequent controls during the phase of highest probability of relapse, especially in high-risk patients, might increase the clinical efficacy of MRD monitoring.
In contrast, the outcome after hematological relapse was poor, regardless the relatively high rate of second CR achieved, in approximately 80% of patients, and the high proportion of responding patients receiving an SCT as intensification. Remarkably, none of the patients with persistent MRD after salvage chemotherapy attained a durable response, including five patients submitted to alloSCT. Therefore, MRD-positive response identifies a subset of patients with a highly resistant disease unresponsive even to eventual graft-versus-leukemia mechanisms developing after allogeneic transplantation. This observation differed from previous studies describing frequent MRD clearance following alloSCT, and could be attributed to differences in front-line therapy received. 34, 35 Moreover, almost 80% of patients who achieved a molecular response and underwent subsequently an autologous SCT experienced a second relapse. Altogether, these results strengthen the need of an alternative approach for patients presenting with an overt hematological relapse, especially when a molecular response is not obtained.
ATO currently stands as the first option for patients relapsing after ATRA-containing therapy, based on its high antileukemic efficacy, with a CR rate over 80%, shown in retrospective studies. [10] [11] [12] [13] [14] [15] [16] [17] Moreover, the mild toxicity profile of this agent, devoid of mielotoxicity, is an additional potential advantage of ATO over chemotherapy-based salvage strategies, and could translate in a decreased treatment-related mortality. Nonetheless, the beneficial impact of ATO over chemotherapy-based strategies should be confirmed in prospective trials or accurate matched-pair analysis. Moreover, several issues concerning the use of ATO in this context, such as the required number of cycles of ATO or the adequate timing of SCT in this setting, remain to be defined. Gemtuzumab ozogamycin (GO), a monoclonal antibody against CD33 conjugated to calicheamicin, also shows high activity both in newly diagnosed APL and relapsed APL, and could be considered in certain circumstances, such as the lack of molecular clearance. [36] [37] [38] In conclusion, early institution of salvage therapy in patients with APL presenting a molecular failure resulted in a beneficial outcome compared to that of patients with overt morphologic relapse. Nonetheless, once hematological relapse occurs, the prognosis of these patients is poor, and the salvage strategy herein administered, based on high-dose ara-C and ATRA followed by SCT, revealed ineffective in most cases. Therefore, the use of new agents such as arsenicals or the conjugated monoclonal antibody GO in this setting is warranted, and should be analyzed in prospective trials.
